Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon
A. Paolo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paola Queirolo, Nicola Pimpinelli(University of Florence), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Antonio Muggiano, Ester Simeone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Gaetana Rinaldi(AOL (United States)), Mario Mandalà(University of Perugia)
Cited by 20
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k